Teva Photo: ASAP Creative Shutterstock FDA to respond to Teva migraine drug application in Sep

Migraine treatment fremanezumab is one of the main branded drugs on which Teva is banking on in the coming years.

Tal Levy Photo: Eyal Fisher Ferring invests $15m in Israeli unit Bio-Technology General

New technologies and production lines at BTG Israel plant will support the development of new treatments in reproductive medicine and women’s health.

Opko  photo: Tamar Matsafi Recommendation against indemnity for test hits Opko

The company's share price dropped 18% in trading on Nasdaq and TASE after Novitas recommended against Medicare reimbursement for the prostate cancer test.

Teva Photo: Reuters Ammar Awad Teva on FDA name and shame list

The US Food and Drug Administration has published a list of pharma companies that "game the system" to block generic competition.

Amir Kishon Photo: PR Merchavia invests in digital therapeutics co RMDY

RMDY deals with a constantly changing patient management market by reinventing itself.

DNA. Photo: Shutterstock Israeli genomic analysis co Genoox raises $6m

The startup strives to make it easier for doctors, clinicians and researchers to analyze and act on genetic sequencing results by applying various clinical applications.

Marius Nacht, photo: Tamar Matsafi Credit Suisse to raise $250m for Nacht's aMoon Fund

aMoon's $500 million second fund will be Israel's largest-ever life science venture capital fund.

Warren Buffett Photo: ASAP Creative Buffett's Berkshire Hathaway doubles Teva stake

Teva's share price jumped in after-market trading after it was revealed that Berkshire Hathaway now has a 3.45% holding in Teva.

BrainQ Photo; PR Israeli AI neuro-disorders co BrainQ raises $8.8m

The Jerusalem-based digital therapeutics company will use the funding to further develop its non-invasive, BCI-based simulation device towards commercialization activities in various markets.

Arie Belldegrun Photo: PR Arie Belldegrun is not resting on his laurels

In Israel for the MIXiii Biomed 2018 conference, the Kite Pharma founder tells "Globes" about his latest ventures after last year's $12 billion exit.

medical research image: Shutterstock Life science investment in Israel soars

The industry raised a record $1.2 billion in 2017, and employment in it is growing rapidly.

Teva Photo: Reuters Ammar Awad Teva exec soothes on debt

Teva investor relations head Tomer Amitai: Our strong first quarter cash flow and bond issue reduced our debt to less than $30 billion.

Perrigo's Yerucham factory Photo: Reuters FDA delays approving Perrigo's generic Teva inhaler

Teva's sales of its ProAir inhaler rose 7% to $130 million in the first quarter.

Migraine Photo: Shutterstock Neurolief develops non-invasive migraine treatment

The Israeli company hopes that its neuro-modulation system will provide an alternative to drugs.

Aharon Aharon Innovation Authority set to bring pharma cos to Israel

Two major pharmaceuticals firms will set up development centers in Israel as part of the Innovation Authority's Track 35 program.

Teva CFO Michael McClellan Photo: Company website Teva CFO: There's more work to do

Mike McClellan talks to "Globes" about competition for Copaxone and prospects for FDA approval of Teva's migraine treatment.

Brendan Mullen Photo: PR American College of Cardiology seeks startups

Leading US cardiologists have come to Israel to select 10 digital health and medical device startups for a pilot project.

Dr. Elan Ziv Photo; PR ConTIPI Medical develops tampon-like medical devices

The company's first product treated incontinence while its latest insert is for pelvic prolapse.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018